Dermatol. praxi. 2019;13(3):115
Dermatol. praxi. 2019;13(3):119-121
Subcorneal pustular dermatosis is a rare, chronic, reccurent pustular eruption characterized histopathologically by subcornealpustules that contain abundant neutrophils. The condition was originally described in 1956 by Sneddon and Wilkinson, whoseparated SPD from other previously unclassified pustular eruptions. This article reviews etiopathogenesis, clinical findings,differencial diagnosis and treatment.
Dermatol. praxi. 2019;13(3):122-124
Psoriasis is a chronic inflammatory skin disease, often associated with other comorbidities. Over one third of patients suffer frompsoriatic arthritis, patients more frequently develop metabolic syndrome and cardiovascular events, which subsequently lead tolife-shortening. Therefore, it is necessary to regularly monitor patients for cardiovascular risk factors in cooperation with generalpractitioner and corresponding specialists. Early detection and treatment of metabolic syndrome might prevent developmentof cardiovascular diseases as well as improve the psoriasis severity.
Dermatol. praxi. 2019;13(3):126-130
Sarcoidosis is a systemic inflammatory non-infectious granulomatous disease that affects mainly lungs. Skin involvement is presentin about a third of cases. However, many patients are healed spontaneously without any consequences, sarcoidosis can leadto a formation of granulomas in various tissues, later to a tissue remodeling and finally to a destruction of the tissue. Currently,we are able to diagnose and treat sarcoidosis quite well, but we are facing difficulties answering the question of what causes thedisease and its great clinical variability.
Dermatol. praxi. 2019;13(3):131-133
The article summarizes the treatment options and principles for atopic dermatitis (AD) in children which are based on the knowledge ofaetiopathogenesis and pathophysiology of AD. The mainstays of AD treatment have remained the same; however, some recommendationshave changed due to updated knowledge (e. g. atopic skin hygiene, pattern of use of local corticosteroids and local immunomodulators).Due to updated knowledge on AD and a wide choice of local agents, the management of atopic patients can be individualized andcontinues to improve. Biological therapy, which is still in the phase of clinical trials, appears to be most effective...
Dermatol. praxi. 2019;13(3):134-136
Nutrition is an important factor in chronic wound and sore healing. It provides building blocks and micronutrients which take partin healing processes. Good blood circulation and healability of wound are the basic conditions. In wounds that are not possibleto be healed nutrition enhances a quality of life. In poor blood circulation nutrition impact is diminished. An appropriate incomeof proteins is essential, important micronutrients are vitamins C, E, A, zinc, copper, selenium and others. The wound needs alsoenergy for healing in all healing pfases. An enhanced protein income plays its role in pressure ulcers prevention.
Dermatol. praxi. 2019;13(3):140-142
Differential diagnosis of genital ulcers is quite wide. Venerological clinics are certainly dominated by infectious ulcers, we also have tothink about ulcers of non-infectious etiology. The case report below presents an unusual description of a noninfectious genital ulcer case.
Dermatol. praxi. 2019;13(3):143-146
Wells‘ syndrome is a rare recurrent granulomatous dermatitis with eosinophilia in blood count. Clinically it resembles bacterialcellulitis. The diagnosis is established by histopatological findings, where typical feature called „flame figures“ are found.
Dermatol. praxi. 2019;13(3):157-158
Dermatol. praxi. 2019;13(3):138-139
Athlete’s foot – Tinea pedis is common fungal disease which could be seen not only in adults. The article sums up over the countertreatment options. There is also description of preventive procedures which increase efficiency of treatment and which protectpatient against the recurrence.
Dermatol. praxi. 2019;13(3)
Cutaneous T-cell lymphoma are rare, in advance stage almost incurable disease, treatment options in advance stage of the disease are limited. In randomised, open – label, multicentric clinical phase 3 study (ALCANZA) it has been compared effect of brentuximab vedotin (BV) in dose 1.8 mg/kg once every 3 weeks and investigator´s choice (IC) - oral methotrexate 5-50 mg once weekly or bexarotene 300 mg/m2 once per day) – both drugs for up to 48 weeeks. Primary endpoint of study was to assess objective response lasting at least 4 months (ORR4). Between AUG-2012 and JUL-2015, total of 131 patients (66 in BV arm and 67 in IC arm) has been enrolled....
Dermatol. praxi. 2019;13(3):155-156
Dermatol. praxi. 2019;13(3)